​

Avenue Therapeutics Stock (NASDAQ:ATXI)

OwnershipFinancialsChart
Avenue Therapeutics by TradingView

Previous Close

$0.40

52W Range

$0.17 - $3.54

50D Avg

$0.29

200D Avg

$1.03

Market Cap

$1.43M

Avg Vol (3M)

$6.99K

Beta

-0.09

Div Yield

-

ATXI Company Profile

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Jun 27, 2017

Website

ATXI Performance

ATXI Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-11.28M$-14.54M$-8.04M
Net Income$-11.65M$-10.38M$2.05M
EBITDA$-11.28M$4.05M-
Basic EPS$-0.90$-73.60$0.94
Diluted EPS$-0.90$-73.48$0.94

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
MTVAMetaVia Inc.
ADTXAditxt, Inc.
ENSCEnsysce Biosciences, Inc.
DRMADermata Therapeutics, Inc.
REVBRevelation Biosciences, Inc.
UNCYUnicycive Therapeutics, Inc.
PALIPalisade Bio, Inc.